Advancing Therapies from Discovery to Patients Through Novel Target Evaluation, Validation of Meaningful Surrogate Endpoints, & Optimized Patient Stratification to be the First to Market in New Indications
Thank you to our speakers, sponsors, and delegates who joined us in Boston for the summit! If you are interested in the 2027 event, please get in touch at info@hansonwade.com
The 6th Rare & Genetic Kidney Disease Drug Development Summit was the only industry-focused forum dedicated to advancing therapies for rare and inherited renal diseases. This meeting brought together leading experts across discovery, translational, clinical, regulatory strategy, and patient engagement.
With insights from 20+ expert speakers from Novartis, Takeda, Boehringer Ingelheim, Vertex Pharmaceuticals, and more, the summit offered a unique opportunity to hear how leading organizations were navigating the realities of developing treatments for rare kidney diseases, including:
- Decoding the underlying mechanistic renal biology
- Identifying critical surrogate endpoints in clinical trials
- Addressing the practical challenges of trial design, patient recruitment, and real-world data integration.
Through candid discussions on key decision points and lessons learned, attendees were able to benchmark their strategies and gain perspective on the approaches shaping the next wave of renal therapeutics.
As rare kidney drug development continued to gain momentum through recent approvals, expanding genetic insights, and growing regulatory focus on meaningful endpoints, the summit provided a timely platform to align on the strategies needed to accelerate the next generation of renal therapeutics.
There is such a sense of camaraderie at the Rare & Genetic Kidney Disease Drug Development Summit. All stakeholders understand the significant unmet needs and are working collaboratively to advance the field. This meeting is a great way to quickly build knowledge, insights, and connections
Executive Director, Alport Syndrome Foundation
The overall openness to share information and interact with others with an interest in rare kidney diseases made this a valuable and collaborative experience
Director - Early Development, Calliditas Therapeutics
Speakers are excellent and the topics are well-chosen. The speed networking rounds are a really great way to meet people and companies.
Owner, Trillium Medical Ventures
It was a well planned, well developed conference with pertinent information presented.
Explore the 2026 Full Event Guide
- See how companies are tackling challenges from preclinical target validation through clinical development, payer engagement, and asset evaluation
- Preview strategies across 5+ rare kidney disease indications
- Insights from the companies and experts advancing renal pipelines
- Learn how teams are addressing surrogate endpoints, clinical trial design, and patient recruitment
- Share key insights with internal stakeholders to align your team
Attending Companies Included
2026 Partners
Explore Related Events
Explore the Agenda
Hear the latest breakthroughs in biomarker validation, surrogate endpoints, and clinical trial design through a packed agenda featuring 3 expert panel discussions, 3 pre-conference workshops, 2 interactive roundtables, and 12+ data-driven case study presentations.
Partner With Us
Position yourself alongside leading solution providers supporting rare and genetic kidney disease pipelines. Whether your expertise lies in preclinical or clinical research, novel biomarkers for diagnosis, stratification or monitoring, imaging, or genetic testing, ensure your brand is at the center of key conversations around clinical development, endpoint validation, and trial execution
Join Biopharma Experts
Engage with a uniquely focused audience of rare and genetic kidney disease decision-makers and be part of high-value conversations with like-minded attendees across all stages of drug development, building critical connections through dedicated networking opportunities